Akari Therapeutics PLC (AKTX) Stock Rating Upgraded by Zacks Investment Research

Akari Therapeutics PLC (NASDAQ:AKTX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company’s lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. “

Several other analysts also recently commented on AKTX. Canaccord Genuity reaffirmed a “buy” rating and set a $15.00 target price on shares of Akari Therapeutics PLC in a report on Friday, September 22nd. William Blair raised shares of Akari Therapeutics PLC from a “market perform” rating to an “outperform” rating in a report on Friday, September 22nd. Chardan Capital reaffirmed a “neutral” rating on shares of Akari Therapeutics PLC in a report on Sunday, September 17th. Finally, ValuEngine raised shares of Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Monday, September 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $8.00.

Akari Therapeutics PLC (NASDAQ AKTX) opened at $4.28 on Monday. Akari Therapeutics PLC has a 52 week low of $3.18 and a 52 week high of $22.20.

WARNING: This report was first published by Week Herald and is owned by of Week Herald. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://weekherald.com/2017/11/15/akari-therapeutics-plc-aktx-stock-rating-upgraded-by-zacks-investment-research.html.

An institutional investor recently raised its position in Akari Therapeutics PLC stock. VHCP Management II LLC increased its stake in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 15.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 426,297 shares of the biopharmaceutical company’s stock after buying an additional 56,807 shares during the period. Akari Therapeutics PLC accounts for about 0.8% of VHCP Management II LLC’s portfolio, making the stock its 13th largest holding. VHCP Management II LLC owned 3.62% of Akari Therapeutics PLC worth $1,965,000 as of its most recent filing with the SEC. Institutional investors own 26.97% of the company’s stock.

Akari Therapeutics PLC Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply